Cas:53439-81-9 5H-benzo[c][1,8]naphthyridin-6-one manufacturer & supplier

Chemical Name:5H-benzo[c][1,8]naphthyridin-6-one

CAS.NO:53439-81-9

Synonyms:xu1

Molecular Formula:C₁₂H₈N₂O

Molecular Weight:196.20500

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.01000

Exact Mass:196.06400

LogP:2.48860

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like xu1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,xu1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,xu1 Use and application,xu1 technical grade,usp/ep/jp grade.

Related News: Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage. 5H-benzo[c][1,8]naphthyridin-6-one manufacturer The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” 5H-benzo[c][1,8]naphthyridin-6-one supplier At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 5H-benzo[c][1,8]naphthyridin-6-one vendor Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage. 5H-benzo[c][1,8]naphthyridin-6-one factory Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.